Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077948 · ClinicalTrials.gov registry record · Phase 3
Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure
A Phase 3 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 175
- Enrollment target
NCT00077948 is a Phase 3 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 175 participants.
The verdict
NCT00077948, a Phase 3 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 175 participants
- Enrollment target
Study Summary
Beta-blocker medications have been shown to improve heart function and prolong the lives of patients with chronic heart failure (CHF). Some people with advanced CHF have difficulty taking beta-blocker medications due to troublesome side effects, such as low blood pressure and/or low heart rate, severe tiredness, dizziness, or shortness of breath. In other words, they have difficulty tolerating beta-blocker medications. The purpose of this study is to determine if enoximone can improve a patient's ability to tolerate a beta-blocker medication.
Interventions
- DRUG Metoprolol succinate
- DRUG Placebo to match metoprolol succinate
- DRUG Enoximone
- DRUG Placebo to match enoximone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2003-07 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077948
The ClinicalTrials.gov registry entry for NCT00077948 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Metoprolol succinate is the first listed.
NCT00077948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00077948 about?
NCT00077948 is a clinical study titled "Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure". Beta-blocker medications have been shown to improve heart function and prolong the lives of patients with chronic heart failure (CHF). Some people with advanced CHF have difficulty taking beta-blocker medications due to troublesome side effects, such as low blood pressure and/or low heart rate, seve...
What is the current status of trial NCT00077948?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 175 participants. The study started on 2003-07. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00077948?
The interventions under investigation include: Metoprolol succinate (DRUG), Placebo to match metoprolol succinate (DRUG), Enoximone (DRUG), Placebo to match enoximone (DRUG).
Who is sponsoring clinical trial NCT00077948?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.